PR064846: Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure
Abstract
Although selective serotonin reuptake inhibitors (SSRIs) are routinely prescribed for acute stress disorder and early PTSD and recommended in the VA-DoD best practice guidelines the efficacy of SSRIs as an early intervention for PTSD in service members returning from war-zone duty has still not been determined. Consequently this study was designed to conduct a controlled trial of fluoxetine as an early intervention for recently redeployed soldiers as well as to develop methodologies for understanding the multiple risk factors that may predict outcome. The approval letter has been received from the Brooke Army Medical Center IRB the regional IRB for the Carl R. Darnall Army Medical Center. The IRB has approved the protocol with the caveat that a CRADA must be completed between TEMPVA Research Group Inc and the Carl R. Darnall Army Medical Center. The protocol has now also been approved by the Central Texas Veterans Health Care System IRB and the Research and Development Committee. The review by Kristen R. Katopol, MS, CIM Human Subjects Protection Scientist (AMDEX Corp.) Human Research Protection Office (HRPO) Office of Research Protections (ORP) U.S. Army Medical Research and Materiel Command (USAMRMC) Fort Detrick is in progress. No subjects have been enrolled and will not be enrolled until final approval is obtained from USAMRMC.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2008
- Accession Number
- ADA490860
Entities
People
- Paul B. Hicks
Organizations
- Tempva Research Group Inc.